Selectively willing and conditionally able: HIV vaccine trial participation among women at " high risk" of HIV infection

Vaccine

Volumn 29, Issue 36, 2011, Pages 6130-6135

  Voytek, Chelsea D ^a   Jones, Kevin T ^a   Metzger, David S ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

African AmericanwomenCrack cocaine usersQualitative research; HIV vaccine; Research subject recruitment; Willingness to participate

Indexed keywords

COCAINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ADULT; AFRICAN AMERICAN; ARTICLE; ATTITUDE; CLINICAL ARTICLE; CLINICAL TRIAL (TOPIC); COCAINE DEPENDENCE; ETHNIC GROUP; FEMALE; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; INTERVIEW; MOTIVATION; NEEDLE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSTITUTION; QUALITATIVE RESEARCH; RESEARCH SUBJECT; VACCINATION;

ADULT; AFRICAN AMERICANS; AIDS VACCINES; ALTRUISM; CHOICE BEHAVIOR; CLINICAL TRIALS AS TOPIC; FEMALE; FOCUS GROUPS; HIV; HIV INFECTIONS; HUMANS; INTERVIEWS AS TOPIC; MOTIVATION; PATIENT PARTICIPATION; PROSTITUTION; QUESTIONNAIRES; RISK FACTORS;

EID: 80051473842     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.06.064     Document Type: Article

References (33)

1. Seage G.R., Holte S.E., Metzger D., Koblin B.A., Gross M., Celum C., et al. Are US populations appropriate for trials of human immunodeficiency virus vaccine? The HIVNET Vaccine Preparedness Study. Am J Epidemiol 2001, 153(April (7)):619-627.
2. CDC. Subpopulation Estimates from the HIV Incidence Surveillance System - United States, 2006. MMWR,2008:985-9.
3. Buchbinder S.P., Metch B., Holte S.E., Scheer S., Coletti A., Vittinghoff E. Determinants of enrollment in a preventive HIV vaccine trial: hypothetical versus actual willingness and barriers to participation. J Acquir Immune Defic Syndr 2004, 36(May (1)):604-612.
4. Newman P.A., Duan N., Roberts K.J., Seiden D., Rudy E.T., Swendeman D., et al. HIV vaccine trial participation among ethnic minority communities: barriers, motivators, and implications for recruitment. J Acquir Immune Defic Syndr 2006, 41(February (2)):210-217.
5. Cargill V.A., Stone V.E. HIV/AIDS: a minority health issue. Med Clin North Am 2005, 89(4):895-912.
6. Chandra A., Paul D.P. African American participation in clinical trials: recruitment difficulties and potential remedies. Hosp Top 2003, 81(2):33-38.
7. Brandon D.T., Isaac L.A., LaVeist T.A. The legacy of Tuskegee and trust in medical care: is Tuskegee responsible for race differences in mistrust of medical care?. J Natl Med Assoc 2005, 97(7):951-956.
8. Gamble V.N. Under the shadow of Tuskegee: African Americans and health care. Am J Public health 1997, 87(11):1773-1778.
9. Freedman T. Why don't they come to Pike Street and ask us" ?: Black American women's health concerns. Soc Sci Med 1998, 47(7):941-947.
10. Freimuth V.S., Thomas Q.S., Cole S.B., Zook G., Duncan E.T. African Americans' views on research and the Tuskegee syphilis study. Soc Sci Med 2001, 52:797-808.
11. Killien M., Champion B.J., Fernandez-Repollet V., Jackson E., Kagawa-Singer R.D., Kidd M., et al. Involving minority and underrepresented women in clinical trials: the national centers of excellence in women's health. J Women Health Gend Based Med 2000, 9(10):1061-1070.
12. Mills E., Cooper C., Guyatt G., Gilchrist A., Rachlis B., Sulway C., et al. Barriers to participating in an HIV vaccine trial: a systematic review. AIDS (London, England) 2004, 18(November (17)):2235-2242.
13. Corbie-Smith G., Thomas S.B., Williams M.V., Moody-Ayers S. Attitudes and beliefs of African Americans toward participation in medical research. J Gen Intern Med 1999, 14(9):537-546.
14. Kegeles S.M., Johnson M.O., Strauss R.P., Ralston B., Hays R.B., Metzger D.S., et al. How should HIV vaccine efficacy trials be conducted? Diverse U.S. communities speak out. AIDS Educ Prev 2006, 18(December (6)):560-572.
15. Strauss R.P., Sengupta S., Kegeles S., McLellan E., Metzger D., Eyre S., et al. Willingness to volunteer in future preventive HIV vaccine trials: issues and perspectives from three U.S. communities. J Acquir Immune Defic Syndr 2001, 26(January (1)):63-71.
16. Hays R.B., Kegeles S.M. Factors related to the willingness of young gay men to participate in preventive HIV vaccine trials. J Acquir Immune Defic Syndr Hum Retrovirol 1999, 20(2):164-171.
17. Moutsiakas D.L., Chin N.P. Why Blacks do not take part in HIV vaccine trials. J Natl Med Assoc 2007, 99(3):254-257.
18. Sengupta S., Strauss R.P., DeVellis R., Quinn S.C., DeVellis B., Ware W.B. Factors Affecting African-American participation in AIDS research. J Acquir Immune Defic Syndr 2000, 24(3):275-284.
19. Colfax G., Buchbinder S., Vamshidar G., Celum C., McKirnan D., Neidig J., et al. Motivations for participating in an HIV vaccine efficacy trial. J Acquir Immune Defic Syndr 2005, 39(July (3)):359-364.
20. Newman P.A., Yim S., Daley A., Walisser R., Halpenny R., Cunningham W., et al. " Once Bitten Twice Shy": participant perspectives in the aftermath of an early HIV vaccine trial termination. Vaccine 2011, 29(3):451-458.
21. Guest G., McLellan-Lemal E., Matia D.M., Pickard R., Fuchs J., McKirnan D., et al. HIV vaccine efficacy trial participation: men who have sex with men's experiences of risk reduction counselling and perceptions of risk behaviour change. AIDS Care 2005, 17(January (1)):46-57.
22. Rudy E.T., Newman P.A., Duan N., Kelly E.M., Roberts K.J., Seiden D.S. HIV vaccine acceptability among women at risk: perceived barriers and facilitators to future HIV vaccine uptake. AIDS Educ Prev 2005, 17(June (3)):253-267.
23. Koblin B.A., Heagerty P., Sheon A., Buchbinder S., Celum C., Douglas J.M., et al. Readiness of high-risk populations in the HIV Network for Prevention Trials to participate in HIV vaccine efficacy trials in the United States. AIDS 1998, 12(May (7)):785-793.
24. Frew P.M., del Rio C., Lu L., Clifton S., Mulligan M.J. Understanding differences in enrollment outcomes among high-risk populations recruited to a phase IIb HIV vaccine trial. J Acquir Immune Defic Syndr 2009, 50(3):314-319.
25. Mills E., Nixon S., Singh S., Dolma S., Nayyar A., Kapoor S. Enrolling women into HIV preventive vaccine trials: an ethical imperative but a logistical challenge. PLoS Med 2006, 3(March (3)):e94.
26. Buchbinder S.P., Mehrotra D.V., Duerr A., Fitzgerald D.W., Mogg R., Li D., et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008, 372(November (9653)):1881-1893.
27. Ulin P.R., Robinson E.T., Tolley E.E. Qualitative methods in public health: a field guide for applied research 2005, Jossey-Bass, San Francisco.
28. Glaser B., Strauss A. The discovery of grounded theory: strategies for qualitative research 1967, Aldine Transaction, Piscataway, NJ.
29. Muhr T. ATLAS.ti: the knowledge workbench 2005, Scientific Software Development, Berlin.
30. Hornblum A. Acres of skin: human experiments at Holmesburg prison, a true story of abuse and exploitation in the name of medical science 1999, Routledge, New York.
31. Fuchs J., Durham M., McLellan-Lemal E., Vittinghoff E., Colfax G., Gurwith M., et al. Negative social impacts among volunteers in an HIV vaccine efficacy trial. J Acquir Immune Defic Syndr 2007, 46(November (3)):362-368.
32. Chesney M.A., Chambers D.B., Kahn J.O. Risk behavior for HIV infection in participants in preventive HIV vaccine trials: a cautionary note. J Acquir Immune Defic Syndr Hum Retrovirol 1997, 16(4):266-271.
33. Johnson M.O. Belief of vaccine receipt in HIV vaccine trials: further cautions. J Acquir Immune Defic Syndr 1999, 21(5):413-416.